Purple Biotech (PPBT) Non-Current Assets (2015 - 2026)

Purple Biotech (PPBT) has 11 years of Non-Current Assets data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Non-Current Assets changed N/A year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $7.7 million, down 72.61% from the prior year.
• Non-Current Assets fell to $7.6 million in Q1 2026 per PPBT's latest filing, from $7.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $28.5 million in Q4 2023 and bottomed at $7.6 million in Q1 2026.
• The 5-year median for Non-Current Assets is $21.4 million (2022), against an average of $18.7 million.
• The widest annual swing landed in 2023, when Non-Current Assets soared 33.46%; it then sank 72.61% in 2025.
• Tracing PPBT's Non-Current Assets over 5 years: stood at $21.4 million in 2022, then soared by 33.46% to $28.5 million in 2023, then decreased by 1.35% to $28.1 million in 2024, then slumped by 72.61% to $7.7 million in 2025, then retreated by 0.88% to $7.6 million in 2026.
• Per Business Quant, the three latest PPBT Non-Current Assets figures stand at $7.6 million (Q1 2026), $7.7 million (Q4 2025), and $28.1 million (Q4 2024).

Peer Comparison